Epigenomic embedding of childhood adversity links to disease risk and chronic inflammation

Darina Czamara PhD[1,2], Dave Juntilla PhD[3,4], Aayah Nounu PhD[3], A. Luise Weihs PhD[5], Mira Erhart MSc[1,6], Lisa Maier PhD[4,7], Miriam Leskien PhD[4,7], Johanna Tuhkanen MSc[8], Aline D. Scherff PhD[2,9], Natan Yusupov PhD[1], Jonas Hagenberg PhD[1,10], Anna S. Fröhlich PhD[1], Vera N. Karlbauer MSc[1,11], Sandra van der Auwera PhD[5,12], Tanja Brückl PhD[1,2], Become Study Team[1], Johannes Kopf-Beck PhD[2,13,14], Samy Egli MD[14], Optima Study team[13,14], Henry Völzke PhD[15,16], Uwe Völker PhD[15,17], Antoine Weihs PhD[5,12], Alexander Teumer PhD[5,15], Juliane Winkelmann PhD[2,18], Holger Prokisch PhD[18,19,20], Christian Gieger PhD[3,20], Janine Knauer-Arloth PhD[1], Lisa Feldmann PhD[2,9], Lucas Miranda PhD[22], Bertram Müller-Myhsok PhD[23], Boadie W. Dunlop MD[24], W. Edward Craighead PhD[25], Jennifer C. Felger PhD[25,26], Andrew H. Miller MD[25], Charles B. Nemeroff MD[27], Ferdinand Hoffmann PhD[28,29], Sonja Entringer PhD[28,29,30] Claudia Buss PhD[28,29,30,31], Sibylle M. Winter MD[30,32], Natalie Matosin PhD[33,34], Helen S. Mayberg MD[25,35], Christine M. Heim PhD[28,30,36], Marie Standl PhD[7,21], Jari Lahti PhD[8], Katri Räikkönen PhD[8,37], Ellen Greimel PhD[2,9], Gerd Schulte-Körne MD[2,9], Hans J. Grabe MD[5,12], Annette Peters PhD[2,4,7,20], Melanie Waldenberger PhD[2,3,20], Elisabeth B. Binder PhD[1,2]

[1] Max Planck Institute of Psychiatry, Department Genes and Environment, Munich, Germany

[2] German Center for Mental Health (DZPG), Partner Site Munich-Augsburg, Munich, Germany

[3] Research Unit Molecular Epidemiology, Institute of Epidemiology, Helmholtz Munich, Neuherberg, Germany

[4] Institute for Medical Information Processing, Biometry and Epidemiology-IBE, Medical Faculty, LMU Munich, Munich, Germany

[5] Department of Psychiatry and Psychotherapy, University Medicine Greifswald, Greifswald, Germany

[6] International Max Planck Research School for Translational Psychiatry, Munich, Germany

[7] Institute of Epidemiology, Helmholtz Zentrum München - German Research Center for Environmental Health, Neuherberg, Germany

[8] Department of Psychology and Logopedics, Faculty of Medicine, University of Helsinki, Finland

[9] Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, LMU University Hospital, LMU Munich, Munich, Germany

[10] Helmholtz AI, Helmholtz Zentrum München, Neuherberg, Germany

[11] Graduate School of Systemic Neurosciences, Ludwig-Maximilians-Universität, Munich, Germany

[12] German Centre for Neurodegenerative Diseases (DZNE), Site Rostock/Greifswald, Greifswald, Germany

[13] LMU Munich, Department of Psychology, Munich, Germany

[14] Max Planck Institute of Psychiatry, Department Clinical Translation, Munich, Germany

[15] German Centre for Cardiovascular Research (DZHK), Partner Site Greifswald, Greifswald, Germany

[16] Institute for Community Medicine, University Medicine Greifswald, Greifswald, Germany

[17] Interfaculty Institute for Genetics and Functional Genomics, University Medicine Greifswald, Greifswald, Germany

[18] Institute of Neurogenomics, Helmholtz Munich, Helmholtz Munich, Neuherberg, Germany

[19] Institute of Human Genetics, Technical University of Munich, Munich, Germany

[20] German Centre for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich, Germany

[21] German Center for Child and Adolescent Health (DZKJ), Partner Site Munich, Munich, Germany

[22] Department of Machine Learning and Systems Biology, Max Planck Institute of Biochemistry, Martinsried, Germany

[23] Max Planck Institute of Psychiatry, Munich, Germany

[24] Department of Psychiatry and Health Behavior, Medical College of Georgia at Augusta University, Augusta, GA, USA

[25] Department of Psychiatry and Behavioral Sciences, Emory School of Medicine, Atlanta, GA, USA

[26] Winship Cancer Institute, Emory University, Atlanta, GA, USA

[27] Department of Psychiatry and Behavioral Sciences, The University of Texas at Austin Dell Medical School, Austin, TX, USA

[28] Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institute of Medical Psychology, Berlin, Germany

[29] Department of Pediatrics, University of California, Irvine, CA, USA

[30] German Center for Mental Health (DZPG), Partner Site Berlin-Potsdam, Germany

[31] German Center for Child and Adolescent Health (DZKJ), Partner Site Berlin, Germany

[32] Charité Universitätsmedizin Berlin, Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Berlin, Germany

[33] School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW, Australia

[34] Charles Perkins Centre, The University of Sydney, Camperdown, NSW, Australia

[35] Icahn School of Medicine at Mount Sinai, NY, USA

36 Cluster of Excellence NeuroCure (EXC25), Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany

37 Department of Obstetrics and Gynecology, Helsinki University Hospital, Helsinki, Finland

Correspondence to:

Darina Czamara, Max Planck Institute of Psychiatry, Department Genes and Environment, Munich, Germany, email: darina@psych.mpg.de, phone: +4989-30622-8174

Elisabeth B. Binder, Max Planck Institute of Psychiatry, Department Genes and Environment, Munich, Germany, email: binder@psych.mpg.de, phone: +4989-30622-8309

Abstract

Importance

Childhood adversity is a major risk factor for both psychiatric and physical disorders and likely interacts with genetic variation to influence disease vulnerability (gene × environment interplay). DNA methylation constitutes a possible mediator of these combined effects. Given the important role of the immune system for both the lasting consequences of childhood adversity and disease risk, this study focuses on mapping the epigenetic embedding in the context of genetic variation in peripheral blood immune cells.

Objective

To determine gene × childhood adversity interplay on DNA methylation

Design

We tested for contextual methylation quantitative trait loci in peripheral blood using linear regression models with DNA methylation as outcome, the interaction of childhood adversity and single nucleotide polymorphisms as predictors, combining results via random-effects meta-analysis.

Setting

Multi-center cohort study combining epidemiological and clinical cohorts

Participants

3,471 adolescents/adults and 780 children were included in the study.

Main Outcome and Measures

The main outcome was DNA methylation assessed using epigenome-wide methylation arrays. Single nucleotide polymorphism genotypes, based on genome-wide genotyping arrays and imputation, as well as childhood adversity, based on parental or self-report were used as predictors. Covariates included genetic sex, age, estimated cell counts and genetic principal components.

Results

We identified 5,120 contextual methylation quantitative trait loci of which 20% successfully replicated in the independent childhood cohorts. Genetic and epigenetic variants within these loci showed enrichment in pathways implicated in the major histocompatibility complex, were linked to both psychiatric and physical disorders in genome-wide studies and differentially methylated with psychiatric disease in postmortem brain. A polygenic interaction reactivity score computed from these genetic variants was associated with plasma levels of interleukin-6 in the UK Biobank cohort in the context of childhood adversity (n=26,901).

Conclusion and relevance

This study highlights the relevance of gene × environment in the epigenetic embedding of childhood adversity in immune cells. Epigenetic and genetic associated with this interplay are linked to immune function. Both are enriched for variants which have been associated with various childhood adversity-linked diseases, including psychiatric and physical disorders, supporting this epigenetic embedding in immune cells as one common pathway from exposure to disease.

Introduction

Childhood adversity (CA) has been shown to have long-lasting and pervasive consequences on child development that persist into adulthood and even old age, with an increased risk reported across psychiatric traits and other medical conditions, including metabolic disease, cardiovascular, autoimmune and neurodegenerative disorders [1-4] and thus leading to reduced life expectancy [5]. Consequently, lasting biological sequelae of CA have been reported for multiple tissues, including effects on brain structure and function [6-8] and other organ systems [4]. The impact of CA on the immune system has been of particular interest, as it may – at least in part – mediate increased risk for psychiatric as well as physical disorders, possibly representing a common etiological pathway underlying some of the multifaceted downstream health consequences of CA [2].

A variety of data gathered from preclinical, clinical, and epidemiological studies suggests lasting consequences of CA exposure on immune function, reflected in increased chronic inflammation and altered inflammatory responses [4,9,10]. CA has been repeatedly associated with higher plasma concentrations of blood-based markers of inflammation in adulthood, such as interleukin-6 (IL-6) [4]. Chronically altered immune profiles, especially proinflammatory ones, have been linked to a number of the disorders for which risk is increased by CA exposure, including major depression, cardiovascular and metabolic disease and neurodegenerative disorders [11-16].

An important question thus arises as to how such lasting effects of early environmental experiences are embedded in the immune system. Here, epigenetic mechanisms, including DNA methylation (DNAm), have been proposed, supported by consistent evidence across human and animal studies [17-21]. CA has been associated with DNAm changes in immune cells of candidate genes such as *FKBP5*, and activation of proinflammatory signaling cascades [22]. Genome-wide approaches investigating the effects of CA on DNAm in peripheral blood cells,

however, have not yet been conclusive with few consistent replications of CA-associated changes in DNAm-sites, likely due to complex interaction patterns [23,24]. Indeed, DNAm is influenced not only by a variety of environmental factors but also by genetic ones, reflecting the complex architecture of downstream disease risk. It has been proposed that most complex traits are determined by currently poorly understood interactions between an individual's genetic background and their environment [25].

Gene × environment (G×E) interactions – where an individual's genetic makeup influences their response to environmental exposures – have been difficult to detect, particularly when examining broad, distal phenotypes. This is likely due to the complexity and variability of the outcomes and the environmental risk factors, as well as the large sample sizes required to achieve sufficient statistical power. Context-dependent quantitative trait locus analysis for molecular outcomes has been proposed as a more tractable way to identify G×E interactions [26]. Previous studies have successfully identified such contextual QTLs on the level of gene expression, chromatin accessibility and DNAm, exploring cell-type or disease risk factors and immune stimuli as contexts, among others [26-32]. However, to best of our knowledge, no study so far has investigated molecular quantitative traits in the context of CA.

We and others have previously shown that G×E interactions are also relevant for predicting DNAm, with the variance in DNAm explained best by a combination of G and prenatal stress or CA [33-35].

These findings justify applying a contextual QTL approach to understand lasting effects of CA on the immune system in the context of genetic variation, with DNAm as a read-out. We hypothesize that relevant G×CA interactions that would have lasting effects on immune function could, at least in part, be mediated by CA-dependent meQTLs. We test for changes in direction or strength of robust peripheral blood meQTLs [36] with exposure to CA in nine cohorts with over 4,000 individuals to map these effects and follow-up with functional and

disease relevant annotations. We use the identified CA-context meQTLs to generate a

polygenic interaction score indicative of DNAm reactivity to early life stress and correlate

this score with immune measures in UK Biobank.

Methods

Sample demographics are given in **Table 1**. Detailed information on included samples, data acquisition and pre-processing as well as statistical methods is given in **eMethods**. In brief, we first tested each cohort independently for interaction of single nucleotide polymorphism (SNP) genotype and CA on DNAm, focusing on significant methylation quantitative trait loci (meQTLs) identified in the GoDMC-consortium [36]. In most of the cohorts, we used the Childhood Trauma Questionnaire [37,38] as well as other validated questionnaires for CA. Afterwards, we combined results across cohorts using random-effects meta-analysis. Identified SNP and CpG-sites were annotated, tested for pathway enrichment and mapped to complex traits. An overview of performed statistical analyses is provided in **eFigure 1**.

Results

We analyzed potential contextual methylation quantitative trait loci (contmeQTLs) in peripheral blood with regard to childhood adversity (CA) in six independent cohorts of adolescents and adults with an overall sample size of 3,471 individuals including 18% with exposure to significant CA (see **Table 1**). An overview of the research question and main results is depicted in the **graphical abstract**.

Identification of robust sex-consistent contmeQTLs in adolescent and adult cohorts

We restricted our search to already established meQTLs. The GoDMC consortium analyzed blood meQTLs in over 30,000 individuals from European ancestry [36] and identified 66,577,913 significant *cis* meQTLs (consisting of 6,316,998 unique SNPs and 183,207 unique CpG-sites, $p< 1x10^{-08}$) and 3,657,300 significant *trans* meQTLs (consisting of 893,991 unique SNPs and 19,147 unique CpGs, $p<1x10^{-14}$), based on a *cis*-window of 1 MB. We used this list of SNP-CpG combinations and first tested for contmeQTLs with CA in each cohort (ALSPAC, BeCOME, BioMD-Y, KORA, SHIP and OPTIMA) separately. Afterwards, we combined results across cohorts using random-effects meta-analysis. Overall, 5,090 contmeQTLs in *cis* and 30 contmeQTLs in *trans* survived multiple testing correction (see **Figure 1A** and **B, eTable 1** and **eTable 2**). ContmeQTLs SNPs and CpG-sites were sex-consistent, without strong cell-type specific effects and in general further apart as compared to all tested combinations (see **eResults 1**). Furthermore, we found enrichment for variance meQTLs and for several chromHMM states, including enhancers (see **eResults 2**).

ContmeQTLs are enriched for pathways implicated in the major histocompatibility (MHC)-protein complex and associated with gene expression of MHC genes

Enrichment for GO terms highlighted several pathways implicated in the major histocompatibility complex (MHC)/human leukocyte antigen (HLA)-complex (located on

chr6:28,477,797-33,448,354, based on hg19, see **Figure 1C**). Genes mapping to contmeQTL

CpG-sites and contmeQTL SNPs were significantly enriched for the following GO terms:

MHC-protein-complex, peptide antigen assembly with MHC-protein complex, the MHC-

class-II-protein-complex, MHC-class-II-protein-complex binding and peptide antigen

assembly (PAA) with MHC-class-II-protein complex. More detailed results on these

enrichments are given in **eResults 3**. The link to the MHC was also evident in expression

quantitative trait methylation (eQTM) analyses in KORA and BeCOME with significant

associations between contmeQTL CpG-sites and gene expression of MHC genes (see **Figure

1D**, **eResults 3** and **eTable3**).

ContmeQTLs overlap with GWAS and EWAS hits

We next checked if contmeQTL SNPs and CpGs had been previously associated with

complex traits. The proportion of overlap with GWAS hits was significantly larger for

contmeQTL SNPs (overlap of 44.7%, n=3,778 SNPs out of 8,425 unique contmeQTL SNPs)

as compared to all tested meQTL SNPs (overlap of 36.8%, n=61,740 SNPs out of 167,600

unique tested SNPs; p=4.11×10^{-49}). We did not only find a higher degree of overlap, but

also significant differences with regards to domains the GWAS hits mapped to: contmeQTL

SNPs mapped significantly more often into the domains 'Autoimmune immunological

disease', 'Endocrine', 'Haematological', 'HLA', 'Mental Disorders', 'Nutritional',

'Pulmonary' (e.g. and 'Surgical' compared to all tested meQTL SNPs (see **Figure 2A**,

eResults 5, **eTable 4** and **eTable 5**). Details on the EWAS overlap are given in **eResults 5**,

eTable 6 and **eTable 7.**

CpG-sites regulated by contmeQTLs are potentially causally related to mental health traits in

blood and brain

We next sought to employ Mendelian Randomization (MR) to check for potential causal relations with disease traits. For this we leveraged the systematic MR-analysis by Richardson et al. [39] who assessed the relationship between CpG-sites and 139 complex traits using blood meQTL SNPs as instruments. We observed a significantly higher overlap: overall, 0.33% of all tested CpG-sites overlapped with CpG-sites identified as causal on any complex traits in [39], whereas 0.6% of contmeQTL CpGs overlapped with this list (p=3.20 $\times$ 10^{-04}, proportional Z-test). We also found differences with regard to domains the complex traits mapped to (see **eTable 8**) with significantly stronger enrichment for 'Autoimmune immunological disease' (e.g. "Rheumatoid arthritis", p=0.04) and 'Mental Disorders' (i.e. "Schizophrenia", p=0.05). Additionally, we found a nominally but not significantly higher overlap, for the trait domains Cardiovascular (e.g. "Coronary artery disease"), "Puberty related" (i.e. "Age at menarche") and "Reproductive" (i.e. "Age at menopause", see **Figure 2B**), reflecting partly the GWAS enrichments reported above.

Given that we assessed evidence for function and disease enrichment of contmeQTL CpGs and contmeQTL SNPs on different levels (overlap with EWAS and GWAS hits, enrichment for significant MR results and eQTMs), we next investigated if any markers showed associations across all these layers, which would underscore the complex mechanisms underlying regulation by contmeQTLs. Overall, 17 contmeQTL CpGs overlapped with eQTMs identified in KORA and had been potentially associated with complex traits in the MR-analysis by Richardson et al. [39]. All these also overlapped with EWAS hits and 16 of the respective contmeQTL SNPs overlapped with GWAS hits for complex traits (see **eResults 6**). In addition, we observed a significant overlap of contmeQTL CpGs and CpG-sites associated with psychiatric diagnosis in a post-mortem brain cohort indicating that some of our hits identified in peripheral tissue might also be relevant in brain.

The overlapping CpGs map to 291 genes including genes with prior evidence for disease relevance (see **eResults 7** and **eTable 10**).

ContmeQTLs replicate in childhood cohorts

Next, we wanted to establish if contmeQTLs identified in adolescents and adults already show significant interaction effects earlier in life. For this we used data from three independent childhood cohorts: GLAKU, Kids2Health and LISA including 780 children (see **Table 2**). Information on childhood trauma itself was available for Kids2Health, and the stressful life events were used as proxy phenotype in GLAKU and LISA (see **eMethods**). Of the initial 5,120 (5,090 in *cis*, 30 in *trans*) contmeQTLs, 1,061 (1,052 in *cis* and 9 in *trans*) could be replicated in the childhood cohorts (see e**Table 11** and **eTable12**) indicating that some contmeQTLs might already be present in early life. The replicated results also revealed enrichments for the MHC complex (see **eResults 8**).

A polygenic interaction reactivity score is associated with higher inflammation in CA-exposed individuals

Next, we computed a polygenic interaction reactivity score, based on the 3,475 LD-clumped SNPs acting as contmeQTLs. This score is the sum of copies of reactive alleles, i.e., alleles associated with higher absolute DNAm changes in the context of CA exposure (see **eMethods** and **eTable 13**). A higher PIRS was associated with higher IL-6 levels in younger UK Biobank participants exposed to CA (N=2,489; p=0.046; beta=6.45, age at most 58 years, based on median split), the effect was flipped for unexposed participants (N=10,268; p=0.0017; beta=-3.382) indicating an interaction between CA exposure and the PIRS (p=0.0362). None of these effects were significant in UK Biobank participants older than 58 years (see **Figure 2C**).

Discussion

In order to map lasting epigenetic effects of CA in immune cells, we investigated meQTLs in the context of CA. We identified over 5,000 significant contmeQTLs in adolescents and adults in peripheral blood - that is meQTLs that were moderated by the exposure of CA - and around 1,000 of these could be replicated in children. SNPs and CpG-sites within these contmeQTLs mapped to genes that were enriched for the MHC-region and eQTM analyses confirmed that differential DNAm at contmeQTL CpGs was associated with altered gene expression, including for *HLA*-genes, supporting their functional relevance. Significant enrichment of contmeQTL SNPs for GWAS hits lends support for the importance of G×E in complex traits. This was in line with the significantly higher enrichment of contmeQTL CpGs in MR associations of blood meQTLs. In agreement with the pleiotropic risk conveyed by CA, enriched traits included mental disorders but also autoimmune, endocrine and other disorders and traits. Computing a polygenic interaction reactivity score from the contmeQTL SNPs, we found an association of a higher score with higher IL-6 levels in CA-exposed individuals, suggesting that increased inflammation could be a common pathway linking CA to various disease outcomes in susceptible individuals.

The results of our study support the importance of G×E for complex traits for which CA is an environmental risk factor. While the role of G×E in CA-related disorders has long been proposed, as for example by the stress-diathesis model [40], mapping specific genes in this context has been more challenging [41]. Genome-wide approaches have also tried to explore this, with some supportive results for major depression as outcome [42]. Overall, however, genome-wide G×E for CA are challenging to conduct and interpret due to the need of very large sample sizes and variability in how both CA and the diverse outcomes are reported and measured [43-45].

Focusing on a) molecular traits as proximal measures and b) more reliably quantifiable outcomes could increase power to robustly detect specific variants within G×CA. Our analysis identified over 5,000 robust contmeQTLs with CA using random effects meta-analysis over 6 independent cohorts with over 3,400 individuals of which 1,061 replicated in childhood cohorts. These contmeQTLs were identified as subset of meQTLs discovered in the largest peripheral blood meQTLs analysis to date with over 30,000 individuals included [36], ensuring robust main genetic effects and increased power by reducing multiple testing burden.

While prior studies using these approaches have focused on disease states, physiological differences or pharmacological challenges [26-32], our results show that contextual QTLs can also capture G×E with external, complex environments such as CA.

In the adult cohorts, we used the Childhood Trauma Questionnaire (available in the BeCOME, OPTIMA and SHIP cohorts) [37,38] as well as other validated questionnaires for CA that all focus on retrospective report of abuse, maltreatment and neglect occurring before the age of eighteen. About 20% of the contmeQTLs identified in adolescents and adults replicated in our three childhood cohorts (N = 780) that ranged in age from 3 to 13 years and used caregiver/parental reports of maltreatment (Kids2Health) or parental/maternal reports of adverse life events such as divorce, severe disease, death or unemployment (LISA and GLAKU). Furthermore, some of the included cohorts are epidemiological (ALSPAC, GLAKU, KORA, LISA and SHIP), while other cohorts have been recruited based on clinical (BeCOME, BioMD-Y, OPTIMA, PReDICT) or exposure characteristics (Kids2Health). We observe similar effects across different instruments and populations and rates of CA indicating that identified interaction effects are not specific for one specific type of CA or for one exposed group.

The amount of replicated contmeQTLs in childhood cohorts was higher than expected by chance which is interesting in the context of data suggesting that psychopathology is more strongly associated with retrospective, subjective measures of childhood maltreatment than prospective ones reflecting a third person perspective [46].

The biological embedding of CA already present in childhood significantly overlapped with the DNAm changes associated with a subjective retrospective report of CA in adulthood. How this early embedding is related to future disease risk will need to be explored in larger and longitudinal studies. Future studies will also need to examine differential effects of developmental timing on contmeQTLs, as it has been suggested that very early childhood is the most sensitive period in shaping DNAm variability [47,48].

Of note, CA contmeQTL SNPs were not enriched for SNPs associated with report of CA in a GWAS [49], suggesting that distinct SNPs may be related to higher risk for exposure/report vs. epigenetic embedding.

ContmeQTLs in immune cells may provide a link between CA and pleiotropic disease outcome that could be mediated by the joint impact of genetic risk variants and CA on immune function. Such lasting embedding in immune cells could be mediated through replenishment effects of affected stem cells [50]. Exposure to CA has been linked to increased risk for a number of psychiatric disorders as well as their earlier onset, increased severity, and increased treatment resistance [51-53]. In addition, CA has also been associated with increased risk for cardiometabolic diseases, autoimmune disorders and neurodegenerative disease in adulthood and older age [4,54], independent of lifestyle factors [55]. This is accompanied by increased measures of allostatic load with CA [56].

Reflecting this, CA-contmeQTLs are linked to pleiotropic disease risk both on the SNP and the CpG-level, including through MR-analysis from blood meQTLs. This supports that

epigenetic embedding requires both genetic susceptibility and environmental exposure. In fact, overlap with GWAS and from MR analyses indicate enrichment for mental disorders but also autoimmune/immunological disorders, including asthma, and cardiovascular disease (see **Figure 2A and B**). They were also enriched for puberty related traits (age at menarche, see **Figure 2B** and **eTable 7**) and exposure to CA has been linked to accelerated puberty timing [57].

While immune system effects have been associated with increased risk for psychiatric disorders [58-60], the epigenetic embedding of SNP×CA may not be restricted to the immune system for a subset of genes. In fact, we found that over 300 contextual meQTL CpGs also showed differential DNAm with psychiatric disorders in the cortex (BA 11) in postmortem brain, more than expected by chance. These CpGs map to 291 genes (see **eTable 10**) of which a number have previously been linked to psychiatric disorders through GWAS or CNV studies (e.g. *C4*, *P2RX7*, *TSNARE1*, *BRD2*, *NOTCH4*, *SHANK2* and others [61-65]), postmortem brain transcriptomics (*GRIN2B*, *HRH1* and others [66,67]) and DNAm analyses (*DDR1* and *PTPRN2* [68,69]). Finally, CpGs with differential DNAm in brain were also located in immune genes including in the *HLA*-locus with *C4* and in *NF-kB1*. The HLA system, including *C4*, has been proposed to be involved in neurodevelopment and neuroplasticity, especially through microglia regulation and synaptic pruning [70,71] and *NF-kB* to impact psychiatric risk through effects in neurons and glial cells [72]. Assuming CA influences multiple systems in the body, our contmeQTLs identified in peripheral blood could hint towards psychiatric disease risk via additional epigenetic effects in the brain. Our findings may also suggest that at least a subset of effects is consistent in different tissues, meaning the peripheral findings act as a proxy for what is happening in the brain (where psychiatric symptoms actually manifest) which has utility for biomarker purposes.

As highlighted above, the identified contmeQTLs support lasting effect of CA and genetic susceptibility on immune regulation via epigenetic changes. This is underscored by an enrichment in genes from the MHC-complex and the fact that eQTM results support that these changes in DNAm also relate to altered expression in *HLA*-genes and other immune regulators. By computing a polygenic interaction reactivity score with the 3,475 LD-clumped contmeQTL SNPs, we could interrogate the combined impact of these changes on the immune system. Indeed, this polygenic score was also significantly associated with higher levels of IL-6 in CA-exposed individuals in UK Biobank (see **Figure 2C**). This supports that some of the CA-associated changes in immune status could be mediated by epigenetic changes resulting from a combined genetic risk and CA exposure.

Elevated IL-6 has previously been associated with exposure to different types of childhood trauma [4,73,74]. Using MR, we have previously reported a potential causal link between elevated IL-6 levels and depressive symptoms [75] which has been confirmed for depression by [76] using data from UK Biobank. Interestingly, several studies have proposed dysregulated IL-6 signaling as a shared mechanisms linking comorbid, and CA-associated, disorders including depression, cardiovascular diseases and autoimmune disorders [77-79].

Conclusions

This study highlights the relevance of G×E in the epigenetic embedding of CA in immune cells and proposes changes in the immune system as one common pathway linking CA to disease risk. The contmeQTL CpGs are associated with altered gene expression of relevant genes regulating inflammation, lending additional support to the role of the immune system in mediating CA-associated disease risk. The identified polygenic interaction reactivity score could serve as biomarker for precision psychiatry, identifying individuals at risk after exposure to CA to support precision psychiatry approaches offering adapted prevention and treatment approaches, as suggested for patients with CA and increased inflammatory tone [1,80].

Tables

Table 1: Demographics of initial cohorts

	ALSPAC n=616	BeCOME n=249	BioMD-Y n=551	KORA n=1,519	OPTIMA n=96	SHIP n=440
Type of cohort	epidemiological	clinical	clinical	epidemiological	clinical	epidemiological
CA [%]	191 (31.0%)	68 (27.3%)	211(38.3%)	201(13.32%)	35(36.5%)	37 (8.4%)
Sex female [%] CA Sex female [%] no CA	98 (51.9%) 217 (51.1%)	47 (69.1%) 111 (61.3%)	142 (67.3%) 218 (64.1%)	97 (48.2%) 698 (53.0%)	24 (68.6%) 29 (47.5%)	27 (72.0%) 212 (52.6%)
Mean age (SD) [yrs] CA Mean age (SD) [yrs] no CA	17.11 (0.98) 17.12 (1.05)	39.04 (12.36) 33.91 (11.86)	15.34 (1.97) 14.94 (2.12)	54.70 (9.40) 58.91 (11.83)	44.60 (14.10) 42.05 (13.37)	47.84 (13.2) 49.90 (13.43)

Table 2: Demographics of replication cohorts

	GLAKU n=239	Kids2Health n=319	LISA n=222
Type of cohort	epidemiological	selected	epidemiological
CA [%]	80 (33.5%)	160 (50.1%)	113(50.9%)
Sex female [%] CA Sex female [%] no CA	39 (48.8%) 84 (52.8%)	73 (45.6%) 68 (42.8%)	49 (43.4%) 45 (41.3%)
Mean age (SD) [yrs] CA Mean age (SD) [yrs] no CA	12.39 (0.47) 12.33 (0.52)	8.31 (2.19) 7.94 (2.00)	6.07 (0.18) 6.07 (0.11)

Figure legends

Figure 1: Identification of contmeQTLs, enrichment analyses and eQTMs

(**A**) Manhattan plot of contmeQTLs: chromosomal position (based on the CpG-site) is depicted on the x-axis, meta-analysis interaction p-values for SNP×CA on the y-axis.

(**B**) Example for a contmeQTLs: rs6142473 (chr20: 34,573,701), located in *CNBD2*, interacts with CA on the DNAm of cg14947478 (chr20: 34,025,962), located in the 1st exon of *GDF5*, a gene which has been associated with autoimmune disorders [81] (genotypes and DNAm levels available in ALSPAC, BeCOME, BioMD-Y and OPTIMA). The methylation level of cg14947478 is depicted on the y-axis, the specific combination of CA (0 or 1) and rs6142473 genotypes (1 or 2) is depicted on the x-axis in ALSPAC (upper left), BeCOME (upper right), BioMD-Y (lower left) and OPTIMA (lower right). Samples exposed to CA are displayed in orange, unexposed samples are displayed in blue. Note that for jitter plotting, the points have been stretched along the x-axis and y-axis.

(**C**) Enrichment for GO terms for genes mapping to SNPs (left) and CpG-sites (right) implicated in contmeQTLs. Overlap indicates the overlap of the genes mapped by closest distance to SNPs/CpGs relative to all genes present in the specific GO term, displayed on the y-axis. -log10(enrichment p-value) is depicted on the x-axis. Only results significant after multiple testing correction are shown. PAA: peptide antigen assembly

(**D**) eQTM analysis in KORA. Scatterplot for the association of cg01376079 DNAm-levels (x-axis) and gene expression of SSH3 (y-axis) in KORA (left). Interaction plot of CA and rs12789637 on cg01376079 in ALSPAC, the combination of SNP and CA is depicted on the x-axis, methylation level on the y-axis. Samples exposed to CA are displayed in orange, unexposed samples are displayed in blue. Note that for jitter plotting, the points have been stretched along the x-axis and y-axis.

Figure 2: GWAS and MR-enrichment and PIRS

(**A**) Barplot for enrichment for GWAS hits. Overlap of all tested SNPs (left) and SNPs acting as contmeQTLs (right) with GWAS domains are depicted. Trait domains with less than 1% proportion in significant contmeQTLs SNPs were grouped into the category "Other". Domains with significantly more overlap with SNPs acting as contmeQTLs are depicted in bold. Only for these domains the percentages are shown in the barplot.

(**B**) Barplot for enrichment for MR hits. Overlap of all tested CpGs (left) and CpGs included in significant contmeQTLs (right) with MR domains are depicted. Trait domains with less than 1% proportion in significant contmeQTLs CpGs were grouped into the category "Other". Domains with more overlap with CpGs regulated by contmeQTLs are depicted in bold. Only for these domains, the percentages are shown in the barplot.

(**C**) Association of PIRS and IL-6 plasma levels in UK Biobank in younger (at most 58 years of age, upper) and the older individuals (over 58 years of age, lower). Normalized IL-6 levels are depicted on the x-axis, PIRS values on the y-axis. Samples exposed to CA are displayed in orange, unexposed samples are displayed in blue.

Funding

ALSPAC: The UK Medical Research Council and Wellcome (Grant ref: 217065/Z/19/Z) and the University of Bristol provide core support for ALSPAC. This publication is the work of the authors and DC will serve as guarantors for the contents of this paper. A comprehensive list of grants funding is available on the ALSPAC website (http://www.bristol.ac.uk/alspac/external/documents/grant-acknowledgements.pdf). Genomewide genotyping data was generated by Sample Logistics and Genotyping Facilities at Wellcome Sanger Institute and LabCorp (Laboratory Corporation of America) using support from 23andMe.

BioMD-Y: This work was supported by the Randebrock Stiftung associated with the Heckscher Hospital, Munich, Germany during the years 2009–2011 on its inception.

GLAKU: The study has been supported by Academy of Finland, University of Helsinki, Hope and Optimism Initiative, Finnish Foundation for Pediatric Research, Sigrid Juselius Foundation, Jalmari and Rauha Ahokas Foundation, Signe and Ane Gyllenberg Foundation, Yrjo Jahnsson Foundation, Juho Vainio Foundation, Emil Aaltonen Foundation, and Ministry of Education and Culture, Finland. The 352 samples were genotyped at the Genotyping and Sequencing Core Facility of the Estonian Genome Centre, University of Tartu. Dr. Lahti has received research support from the Strategic Research Council (SRC) established within the Academy of Finland (decision number: 352700). This research has received funding from the Academy of Finland, Signe and Ane Gyllenberg foundiation, and Juho Vainio foundation.

KORA: The KORA study was initiated and financed by the Helmholtz Zentrum München – German Research Center for Environmental Health, which is funded by the German Federal Ministry of Education and Research (BMBF) and by the State of Bavaria. Data collection in the KORA study is done in cooperation with the University Hospital of Augsburg. The project was funded by the DZPG (German Centre for Mental Health Research) and by the BMBF (German Ministry of Education and Research) (grant no. 01EE2303E). The project received support by the Bavarian State Ministry of Health and Care through the research project DigiMed Bayern (www.digimed-bayern.de).

LISA: The LISA study was mainly supported by grants from the Federal Ministry for Education, Science, Research and Technology and in addition from Helmholtz Zentrum Munich (former GSF), Helmholtz Centre for Environmental Research - UFZ, Leipzig, Research Institute at Marien-Hospital Wesel, Pediatric Practice, Bad Honnef for the first 2 years. The 4 year, 6 year, 10 year and 15 year follow-up examinations of the LISA study were covered from the respective budgets of the involved partners (Helmholtz Zentrum

Munich (former GSF), Helmholtz Centre for Environmental Research - UFZ, Leipzig, Research Institute at Marien-Hospital Wesel, Pediatric Practice, Bad Honnef, IUF – Leibniz-Research Institute for Environmental Medicine at the University of Düsseldorf) and in addition by a grant from the Federal Ministry for Environment (IUF Düsseldorf, FKZ 20462296). This project received funding from the Federal Ministry of Education and Research (Bundesministerium für Bildung und Forschung, BMBF) as part of the German Center for Child and Adolescent Health (DZKJ) under the funding code 01GL2406C (LM, MS). MS received funding from ALLERGEN ERC grant (grant agreement number 949906).

OPTIMA: This study was funded by the Max-Planck-Gesellschaft.

Post-mortem brain study: Post mortem brain tissues received from the New South Wales Brain Tissue Resource Centre at the University of Sydney were supported by the University of Sydney. Research reported in this publication was supported by the National Institute of Alcohol Abuse and Alcoholism of the National Institutes of Health under Award Number NIAAA012725-15. The content is solely the responsibility of the authors and does not represent the official views of the National Institutes of Health.

SHIP: The Study of Health in Pomerania (SHIP) is part of the Community Medicine Research net of the University of Greifswald, Germany, which is funded by the Federal Ministry of Education and Research (grants no. 01ZZ9603, 01ZZ0103, and 01ZZ0403), the Ministry of Cultural Affairs as well as the Social Ministry of the Federal State of Mecklenburg-West Pomerania, and the network 'Greifswald Approach to Individualized Medicine (GANI_MED)' funded by the Federal Ministry of Education and Research (grant 03IS2061A). Genome-wide SNP typing have been supported by a joint grant from Siemens Healthineers, Erlangen, Germany, and the Federal State of Mecklenburg-Western Pomerania. DNA methylation data have been supported by the DZHK (grant 81X3400104).

This research has been conducted using the UK Biobank Resource under Application Number 979695.

Conflicts of interest

CBN is supported by the National Institutes of Health, the National Institute of Mental Health, the Texas Child Mental Health Consortium and the National Institute of Alcohol Abuse and Alcoholism. CBN is a consultant for Abbott Laboratories, Engrail Therapeutics, Clexio Biosciences LTD, Sero (previously Galen Mental Health LLC), Sage Therapeutics, Senseye Inc, Precisement Health, Autobahn Therapeutics Inc, EMA Wellness, Denovo Biopharma LLC, Alvogen, Acadia Pharmaceuticals, Inc, Reunion Neuroscience, Kivira Health, Inc, Wave Neuroscience, Patient Square Capital LP, Invisalert Solutions Inc., Bluecarta Inc., Incannex Healthcare Inc., and Neurocrine Biosciences, LLC. Charles Nemeroff owns the following patents: Method and devices for transdermal delivery of lithium (US 6,375,990B1), Method of assessing antidepressant drug therapy via transport inhibition of monoamine neurotransmitters by ex vivo assay (US 7,148,027B2), Compounds, Compositions, Methods of Synthesis, and Methods of Treatment (CRF Receptor Binding Ligand) (US 8,551, 996 B2). Charles Nemeroff owns stock in Corcept Therapeutics Company, EMA Wellness, Precisement Health, Relmada Therapeutics Inc, Signant Health, Galen Mental Health LLC, Kivira Health, Inc., Denovo Biopharma LLC, and Senseye Inc. All other authors report no conflicts of interest.

Data availability

Due to ethical issues and consent, datasets analyzed during the current study are not publicly available. Interested researchers can obtain a deidentified dataset after approval from the respective study boards.

Code availability

The code for the main analyses is available at:
https://github.com/darinacz/contextual_meQTLs.

Authors' contributions

DC: study design, data analysis, data interpretation, writing of manuscript

DJ: data analysis, data interpretation

AN: data analysis, data interpretation

ALW: data analysis, data interpretation

ME: data analysis, data interpretation

LMa: data analysis, data interpretation

ML: data analysis, data interpretation

JT: data analysis, data interpretation

ADS: data collection, data interpretation

NY: data analysis, data interpretation

JH: data analysis, data interpretation

ASF: data analysis, data interpretation

VNK: data analysis, data interpretation

SA: data analysis, data interpretation

TB: data collection, data interpretation

JKB: data collection, data interpretation

SE: data collection, data interpretation

HV: data collection, data interpretation

UV: data collection, data interpretation

AW: data collection, data interpretation

AT: data collection, data interpretation

JW: data collection, data interpretation

HP: data collection, data interpretation

CG: data collection, data interpretation

JKA: data analysis, data interpretation

LF: data collection, data interpretation

LMi: data analysis, data interpretation

BMM: data analysis, data interpretation

BWD: data collection

WEC: data collection

JCF: data collection

AHM: data collection

CBN: data collection

FH: data collection

SE: data collection, data interpretation

CB: data collection

SW: data collection

NM: data analysis, data interpretation

HSM: data collection

CMH: data collection, data interpretation

MS: data collection

JL: data collection, data analysis, data interpretation

KR: data collection

EG: data collection, data interpretation

GSK: data collection

HJG: data collection

AP: data collection

MW: data generation, data interpretation, supervision of data analysis

EBB: study design, data interpretation, writing of manuscript

All authors read, edited and approved the final manuscript.

Acknowledgements

We are extremely grateful to all the families who took part in this study, the midwives for their help in recruiting them, and the whole ALSPAC team, which includes interviewers, computer and laboratory technicians, clerical workers, research scientists, volunteers, managers, receptionists and nurses.

The authors would like to thank the Psychiatric Study Center of the Max Planck Institute of Psychiatry - Dr. Norma Grandi, Anna Gossmann, Elisabeth Kappelmann, Karin Hofer, Alexandra Kocsis, Vlada Kolysnik and Gertrud Ernst-Jansen - for organizational support, biomaterial and data collection and the Biomaterial Processing and Repository Unit of the Max Planck Institute of Psychiatry - Tamara Namendorf, Božidar Novak, Marketa Reimann, Angelika Sangl - for the processing and storage of the study's biosamples. The authors further thank Alexandra Bayer, Ines Eidner, Anna Hetzel, Elke Frank-Havemann, Viktoria Messerschmidt, and Ursula Ritter-Bohnensack for assisting with MRI scanning and Julia-Carolin Albrecht, Anastasia Bauer, Anja Betz, Alina Feichtinger, Rebekka Hirsch, Miriam El-Mahdi, Eila Mertens, Carolin Haas, Katharina Kahn, Lisa Kammholz, Sophia Koch, Christof Leininger, Anna Lorenz, Rebecca Meissner, Jessie Osterhaus, Liisbeth Pirn, Christina Rieger, Linda Schuster and Refican Yasar for their help with data collection, study management, the recruitment, and screening of BeCOME participants. The authors' special thanks go to all study participants for participation in the BeCOME and the OPTIMA study. We thank all the GLAKU children and their parents for their enthusiastic participation. We also thank all the research nurses, research assistants, and laboratory personnel involved in the GLAKU study.

We thank all participants for their long-term commitment to the KORA study, the staff for data collection and research data management and the members of the KORA Study Group (https://www.helmholtz-munich.de/en/epi/cohort/kora) who are responsible for the design and conduct of the study.

The authors thank all families for participation in the LISA study and the study teams for their excellent work.

We thank Susann Sauer and Maik Ködel at the Max-Planck-Institute of Psychiatry for the processing of the post mortem brain samples.

The SHIP authors are grateful to Holger Prokisch and Thomas Meitinger (Helmholtz Zentrum München) for the genotyping of the SHIP-TREND-0 cohort.

DC had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

References

1. Teicher MH, Gordon JB, Nemeroff CB. Recognizing the importance of childhood maltreatment as a critical factor in psychiatric diagnoses, treatment, research, prevention, and education. *Mol Psychiatry*. Mar 2022;27(3):1331-1338. doi:10.1038/s41380-021-01367-9

2. Blevins EJ, Slopen N, Koenen KC, Mikesell C, Basu A. Perspectives on Integrating Biological Assessments to Address the Health Effects of Childhood Adversities. *Harv Rev Psychiatry*. Dec 2 2024;doi:10.1097/HRP.0000000000000413

3. Fleck L, Buss C, Bauer M, et al. Early-Life Adversity Predicts Markers of Aging-Related Neuroinflammation, Neurodegeneration, and Cognitive Impairment in Women. *Ann Neurol*. Apr 2025;97(4):642-656. doi:10.1002/ana.27161

4. Entringer S, Heim C. A Brief Historic Review of Research on Early Life Stress and Inflammation across the Lifespan. *Neuroimmunomodulation*. 2025;32(1):24-35. doi:10.1159/000542676

5. Rod NH, Bengtsson J, Budtz-Jorgensen E, et al. Trajectories of childhood adversity and mortality in early adulthood: a population-based cohort study. *Lancet*. Aug 15 2020;396(10249):489-497. doi:10.1016/S0140-6736(20)30621-8

6. Holz NE, Zabihi M, Kia SM, et al. A stable and replicable neural signature of lifespan adversity in the adult brain. *Nat Neurosci*. Sep 2023;26(9):1603-1612. doi:10.1038/s41593-023-01410-8

7. Teicher MH, Samson JA, Anderson CM, Ohashi K. The effects of childhood maltreatment on brain structure, function and connectivity. *Nat Rev Neurosci*. Sep 19 2016;17(10):652-66. doi:10.1038/nrn.2016.111

8. Kaul D, Schwab SG, Mechawar N, Matosin N. How stress physically re-shapes the brain: Impact on brain cell shapes, numbers and connections in psychiatric disorders. *Neurosci Biobehav Rev*. May 2021;124:193-215. doi:10.1016/j.neubiorev.2021.01.025

9. Baumeister D, Akhtar R, Ciufolini S, Pariante CM, Mondelli V. Childhood trauma and adulthood inflammation: a meta-analysis of peripheral C-reactive protein, interleukin-6 and tumour necrosis factor-alpha. *Mol Psychiatry*. May 2016;21(5):642-9. doi:10.1038/mp.2015.67

10. Danese A, Lewis SJ. Psychoneuroimmunology of Early-Life Stress: The Hidden Wounds of Childhood Trauma? *Neuropsychopharmacology*. Jan 2017;42(1):99-114. doi:10.1038/npp.2016.198

11. Libby P. Inflammation in atherosclerosis. *Nature*. Dec 19-26 2002;420(6917):868-74. doi:10.1038/nature01323

12. Miller AH, Raison CL. The role of inflammation in depression: from evolutionary imperative to modern treatment target. *Nat Rev Immunol*. Jan 2016;16(1):22-34. doi:10.1038/nri.2015.5

13. Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. *Nat Rev Immunol*. Feb 2011;11(2):98-107. doi:10.1038/nri2925

14. Amor S, Peferoen LA, Vogel DY, et al. Inflammation in neurodegenerative diseases--an update. *Immunology*. Jun 2014;142(2):151-66. doi:10.1111/imm.12233

15. Cha J, Raj D, Choi KS, et al. Impact of Inflammation on White Matter Integrity and Functional Connectivity in Chronic Major Depressive Disorder. *Biol Psychiatry*. Jul 7 2025;doi:10.1016/j.biopsych.2025.06.026

16.   Syed SA, Beurel E, Loewenstein DA, et al. Defective Inflammatory Pathways in Never-Treated Depressed Patients Are Associated with Poor Treatment Response. *Neuron*. Sep 5 2018;99(5):914-924 e3. doi:10.1016/j.neuron.2018.08.001

17.   Aristizabal MJ, Anreiter I, Halldorsdottir T, et al. Biological embedding of experience: A primer on epigenetics. *Proc Natl Acad Sci U S A*. Sep 22 2020;117(38):23261-23269. doi:10.1073/pnas.1820838116

18.   Turecki G, Meaney MJ. Effects of the Social Environment and Stress on Glucocorticoid Receptor Gene Methylation: A Systematic Review. *Biol Psychiatry*. Jan 15 2016;79(2):87-96. doi:10.1016/j.biopsych.2014.11.022

19.   Klengel T, Binder EB. Epigenetics of Stress-Related Psychiatric Disorders and Gene x Environment Interactions. *Neuron*. Jun 17 2015;86(6):1343-57. doi:10.1016/j.neuron.2015.05.036

20.   Heim C, Binder EB. Current research trends in early life stress and depression: review of human studies on sensitive periods, gene-environment interactions, and epigenetics. *Exp Neurol*. Jan 2012;233(1):102-11. doi:10.1016/j.expneurol.2011.10.032

21.   Matosin N, Halldorsdottir T, Binder EB. Understanding the Molecular Mechanisms Underpinning Gene by Environment Interactions in Psychiatric Disorders: The FKBP5 Model. *Biol Psychiatry*. May 15 2018;83(10):821-830. doi:10.1016/j.biopsych.2018.01.021

22.   Zannas AS, Jia M, Hafner K, et al. Epigenetic upregulation of FKBP5 by aging and stress contributes to NF-kappaB-driven inflammation and cardiovascular risk. *Proc Natl Acad Sci U S A*. Jun 4 2019;116(23):11370-11379. doi:10.1073/pnas.1816847116

23.   Cecil CAM, Zhang Y, Nolte T. Childhood maltreatment and DNA methylation: A systematic review. *Neurosci Biobehav Rev*. May 2020;112:392-409. doi:10.1016/j.neubiorev.2020.02.019

24.   Parade SH, Huffhines L, Daniels TE, Stroud LR, Nugent NR, Tyrka AR. A systematic review of childhood maltreatment and DNA methylation: candidate gene and epigenome-wide approaches. *Transl Psychiatry*. Feb 19 2021;11(1):134. doi:10.1038/s41398-021-01207-y

25.   McAllister K, Mechanic LE, Amos C, et al. Current Challenges and New Opportunities for Gene-Environment Interaction Studies of Complex Diseases. *Am J Epidemiol*. Oct 1 2017;186(7):753-761. doi:10.1093/aje/kwx227

26.   Zhernakova DV, Deelen P, Vermaat M, et al. Identification of context-dependent expression quantitative trait loci in whole blood. *Nat Genet*. Jan 2017;49(1):139-145. doi:10.1038/ng.3737

27.   Baca SC, Singler C, Zacharia S, et al. Genetic determinants of chromatin reveal prostate cancer risk mediated by context-dependent gene regulation. *Nat Genet*. Sep 2022;54(9):1364-1375. doi:10.1038/s41588-022-01168-y

28.   Lea AJ, Peng J, Ayroles JF. Diverse environmental perturbations reveal the evolution and context-dependency of genetic effects on gene expression levels. *Genome Res*. Oct 2022;32(10):1826-1839. doi:10.1101/gr.276430.121

29.   Kim-Hellmuth S, Bechheim M, Putz B, et al. Genetic regulatory effects modified by immune activation contribute to autoimmune disease associations. *Nat Commun*. Aug 16 2017;8(1):266. doi:10.1038/s41467-017-00366-1

30.   Knauer-Arloth J, Hryhorzhevska A, Binder EB. Multiomics Analysis of the Molecular Response to Glucocorticoids: Insights Into Shared Genetic Risk From Psychiatric to Medical Disorders. *Biol Psychiatry*. Apr 15 2025;97(8):794-805. doi:10.1016/j.biopsych.2024.10.004

31.   Natri HM, Del Azodi CB, Peter L, et al. Cell-type-specific and disease-associated expression quantitative trait loci in the human lung. *Nat Genet*. Apr 2024;56(4):595-604. doi:10.1038/s41588-024-01702-0

32.   Hawe JS, Wilson R, Schmid KT, et al. Genetic variation influencing DNA methylation provides insights into molecular mechanisms regulating genomic function. *Nat Genet*. Jan 2022;54(1):18-29. doi:10.1038/s41588-021-00969-x

33.   Teh AL, Pan H, Chen L, et al. The effect of genotype and in utero environment on interindividual variation in neonate DNA methylomes. *Genome Res*. Jul 2014;24(7):1064-74. doi:10.1101/gr.171439.113

34.   Czamara D, Eraslan G, Page CM, et al. Integrated analysis of environmental and genetic influences on cord blood DNA methylation in new-borns. *Nat Commun*. Jun 11 2019;10(1):2548. doi:10.1038/s41467-019-10461-0

35.   Czamara D, Tissink E, Tuhkanen J, et al. Combined effects of genotype and childhood adversity shape variability of DNA methylation across age. *Transl Psychiatry*. Feb 1 2021;11(1):88. doi:10.1038/s41398-020-01147-z

36.   Min JL, Hemani G, Hannon E, et al. Genomic and phenotypic insights from an atlas of genetic effects on DNA methylation. *Nat Genet*. Sep 2021;53(9):1311-1321. doi:10.1038/s41588-021-00923-x

37.   Bernstein DP, Fink L, Handelsman L, et al. Initial reliability and validity of a new retrospective measure of child abuse and neglect. *Am J Psychiatry*. Aug 1994;151(8):1132-6. doi:10.1176/ajp.151.8.1132

38.   Bernstein DP, Stein JA, Newcomb MD, et al. Development and validation of a brief screening version of the Childhood Trauma Questionnaire. *Child Abuse Negl*. Feb 2003;27(2):169-90. doi:10.1016/s0145-2134(02)00541-0

39.   Richardson TG, Haycock PC, Zheng J, et al. Systematic Mendelian randomization framework elucidates hundreds of CpG sites which may mediate the influence of genetic variants on disease. *Hum Mol Genet*. Sep 15 2018;27(18):3293-3304. doi:10.1093/hmg/ddy210

40.   Kendler KS, Eaves LJ. Models for the joint effect of genotype and environment on liability to psychiatric illness. *Am J Psychiatry*. Mar 1986;143(3):279-89. doi:10.1176/ajp.143.3.279

41.   Border R, Johnson EC, Evans LM, et al. No Support for Historical Candidate Gene or Candidate Gene-by-Interaction Hypotheses for Major Depression Across Multiple Large Samples. *Am J Psychiatry*. May 1 2019;176(5):376-387. doi:10.1176/appi.ajp.2018.18070881

42.   Sun Y, Liao Y, Zhang Y, et al. Genome-wide interaction association analysis identifies interactive effects of childhood maltreatment and kynurenine pathway on depression. *Nat Commun*. Feb 18 2025;16(1):1748. doi:10.1038/s41467-025-57066-4

43.   Halldorsdottir T, Binder EB. Gene x Environment Interactions: From Molecular Mechanisms to Behavior. *Annu Rev Psychol*. Jan 3 2017;68:215-241. doi:10.1146/annurev-psych-010416-044053

44.   Bolhuis K, Mulder RH, de Mol CL, et al. Mapping gene by early life stress interactions on child subcortical brain structures: A genome-wide prospective study. *JCPP Adv*. Dec 2022;2(4)doi:10.1002/jcv2.12113

45.   Suppli NP, Andersen KK, Agerbo E, et al. Genome-wide by Environment Interaction Study of Stressful Life Events and Hospital-Treated Depression in the iPSYCH2012 Sample. *Biol Psychiatry Glob Open Sci*. Oct 2022;2(4):400-410. doi:10.1016/j.bpsgos.2021.11.003

46.	Baldwin JR, Coleman O, Francis ER, Danese A. Prospective and Retrospective Measures of Child Maltreatment and Their Association With Psychopathology: A Systematic Review and Meta-Analysis. *JAMA Psychiatry*. Aug 1 2024;81(8):769-781. doi:10.1001/jamapsychiatry.2024.0818

47.	Dunn EC, Soare TW, Zhu Y, et al. Sensitive Periods for the Effect of Childhood Adversity on DNA Methylation: Results From a Prospective, Longitudinal Study. *Biol Psychiatry*. May 15 2019;85(10):838-849. doi:10.1016/j.biopsych.2018.12.023

48.	Lussier AA, Zhu Y, Smith BJ, et al. Sensitive Periods for the Effect of Childhood Adversity on DNA Methylation: Updated Results From a Prospective, Longitudinal Study. *Biol Psychiatry Glob Open Sci*. Jul 2023;3(3):567-571. doi:10.1016/j.bpsgos.2022.04.002

49.	Warrier V, Kwong ASF, Luo M, et al. Gene-environment correlations and causal effects of childhood maltreatment on physical and mental health: a genetically informed approach. *Lancet Psychiatry*. May 2021;8(5):373-386. doi:10.1016/S2215-0366(20)30569-1

50.	Laiosa MD, Tate ER. Fetal Hematopoietic Stem Cells Are the Canaries in the Coal Mine That Portend Later Life Immune Deficiency. *Endocrinology*. Oct 2015;156(10):3458-65. doi:10.1210/en.2015-1347

51.	Lippard ETC, Nemeroff CB. The Devastating Clinical Consequences of Child Abuse and Neglect: Increased Disease Vulnerability and Poor Treatment Response in Mood Disorders. *Am J Psychiatry*. Jan 1 2020;177(1):20-36. doi:10.1176/appi.ajp.2019.19010020

52.	Alley J, Gassen J, Slavich GM. The effects of childhood adversity on twenty-five disease biomarkers and twenty health conditions in adulthood: Differences by sex and stressor type. *Brain Behav Immun*. Jan 2025;123:164-176. doi:10.1016/j.bbi.2024.07.019

53.	Tyrka AR, Burgers DE, Philip NS, Price LH, Carpenter LL. The neurobiological correlates of childhood adversity and implications for treatment. *Acta Psychiatr Scand*. Dec 2013;128(6):434-47. doi:10.1111/acps.12143

54.	Desplats P, Gutierrez AM, Antonelli MC, Frasch MG. Microglial memory of early life stress and inflammation: Susceptibility to neurodegeneration in adulthood. *Neurosci Biobehav Rev*. Oct 2020;117:232-242. doi:10.1016/j.neubiorev.2019.10.013

55.	Layinka O, Souama C, Defina S, et al. Lifestyle behaviours do not moderate the association between childhood maltreatment and comorbid depression and cardiometabolic disease in older adults: a meta-analysis. *BMC Med*. Mar 5 2025;23(1):133. doi:10.1186/s12916-025-03950-1

56.	Danese A, McEwen BS. Adverse childhood experiences, allostasis, allostatic load, and age-related disease. *Physiol Behav*. Apr 12 2012;106(1):29-39. doi:10.1016/j.physbeh.2011.08.019

57.	Ding W, Xu Y, Kondracki AJ, Sun Y. Childhood adversity and accelerated reproductive events: a systematic review and meta-analysis. *Am J Obstet Gynecol*. Mar 2024;230(3):315-329 e31. doi:10.1016/j.ajog.2023.10.005

58.	Danese A, Moffitt TE, Pariante CM, Ambler A, Poulton R, Caspi A. Elevated inflammation levels in depressed adults with a history of childhood maltreatment. *Arch Gen Psychiatry*. Apr 2008;65(4):409-15. doi:10.1001/archpsyc.65.4.409

59.	Worrell C. Navigating a complex landscape - A review of the relationship between inflammation and childhood trauma and the potential roles in the expression of symptoms of depression. *Brain Behav Immun Health*. Mar 2022;20:100418. doi:10.1016/j.bbih.2022.100418

60.   Miller AH, Haroon E, Felger JC. The Immunology of Behavior-Exploring the Role of the Immune System in Brain Health and Illness. *Neuropsychopharmacology*. Jan 2017;42(1):1-4. doi:10.1038/npp.2016.229

61.   Homann OR, Misura K, Lamas E, et al. Whole-genome sequencing in multiplex families with psychoses reveals mutations in the SHANK2 and SMARCA1 genes segregating with illness. *Mol Psychiatry*. Dec 2016;21(12):1690-1695. doi:10.1038/mp.2016.24

62.   Liu J, Cheng Y, Li M, Zhang Z, Li T, Luo XJ. Genome-wide Mendelian randomization identifies actionable novel drug targets for psychiatric disorders. *Neuropsychopharmacology*. Jan 2023;48(2):270-280. doi:10.1038/s41386-022-01456-5

63.   Schrode N, Ho SM, Yamamuro K, et al. Synergistic effects of common schizophrenia risk variants. *Nat Genet*. Oct 2019;51(10):1475-1485. doi:10.1038/s41588-019-0497-5

64.   Sekar A, Bialas AR, de Rivera H, et al. Schizophrenia risk from complex variation of complement component 4. *Nature*. Feb 11 2016;530(7589):177-83. doi:10.1038/nature16549

65.   Wang D, Li D, Dang X, et al. Mendelian randomization reveals causalities between DNA methylation and schizophrenia. *Biol Psychiatry*. Mar 27 2025;doi:10.1016/j.biopsych.2025.03.012

66.   Lori A, Schultebraucks K, Galatzer-Levy I, et al. Transcriptome-wide association study of post-trauma symptom trajectories identified GRIN3B as a potential biomarker for PTSD development. *Neuropsychopharmacology*. Sep 2021;46(10):1811-1820. doi:10.1038/s41386-021-01073-8

67.   Wright C, Shin JH, Rajpurohit A, et al. Altered expression of histamine signaling genes in autism spectrum disorder. *Transl Psychiatry*. May 9 2017;7(5):e1126. doi:10.1038/tp.2017.87

68.   Garcia-Ruiz B, Jimenez E, Aranda S, et al. Associations of altered leukocyte DDR1 promoter methylation and childhood trauma with bipolar disorder and suicidal behavior in euthymic patients. *Mol Psychiatry*. Aug 2024;29(8):2478-2486. doi:10.1038/s41380-024-02522-8

69.   Mohazzab-Hosseinian S, Garcia E, Wiemels J, et al. Effect of parental adverse childhood experiences on intergenerational DNA methylation signatures from peripheral blood mononuclear cells and buccal mucosa. *Transl Psychiatry*. Feb 12 2024;14(1):89. doi:10.1038/s41398-024-02747-9

70.   Bian B, Couvy-Duchesne B, Wray NR, McRae AF. The role of critical immune genes in brain disorders: insights from neuroimaging immunogenetics. *Brain Commun*. 2022;4(2):fcac078. doi:10.1093/braincomms/fcac078

71.   Tamouza R, Krishnamoorthy R, Leboyer M. Understanding the genetic contribution of the human leukocyte antigen system to common major psychiatric disorders in a world pandemic context. *Brain Behav Immun*. Jan 2021;91:731-739. doi:10.1016/j.bbi.2020.09.033

72.   Dresselhaus EC, Meffert MK. Cellular Specificity of NF-kappaB Function in the Nervous System. *Front Immunol*. 2019;10:1043. doi:10.3389/fimmu.2019.01043

73.   Coelho R, Viola TW, Walss-Bass C, Brietzke E, Grassi-Oliveira R. Childhood maltreatment and inflammatory markers: a systematic review. *Acta Psychiatr Scand*. Mar 2014;129(3):180-92. doi:10.1111/acps.12217

74.   Danese A, Baldwin JR. Hidden Wounds? Inflammatory Links Between Childhood Trauma and Psychopathology. *Annu Rev Psychol*. Jan 3 2017;68:517-544. doi:10.1146/annurev-psych-010416-044208

75.   Kappelmann N, Arloth J, Georgakis MK, et al. Dissecting the Association Between Inflammation, Metabolic Dysregulation, and Specific Depressive Symptoms: A Genetic Correlation and 2-Sample Mendelian Randomization Study. *JAMA Psychiatry*. Feb 1 2021;78(2):161-170. doi:10.1001/jamapsychiatry.2020.3436

76.   Kelly KM, Smith JA, Mezuk B. Depression and interleukin-6 signaling: A Mendelian Randomization study. *Brain Behav Immun*. Jul 2021;95:106-114. doi:10.1016/j.bbi.2021.02.019

77.   Khandaker GM, Pearson RM, Zammit S, Lewis G, Jones PB. Association of serum interleukin 6 and C-reactive protein in childhood with depression and psychosis in young adult life: a population-based longitudinal study. *JAMA Psychiatry*. Oct 2014;71(10):1121-8. doi:10.1001/jamapsychiatry.2014.1332

78.   Hunter CA, Jones SA. IL-6 as a keystone cytokine in health and disease. *Nat Immunol*. May 2015;16(5):448-57. doi:10.1038/ni.3153

79.   Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. *Nat Rev Neurosci*. Jan 2008;9(1):46-56. doi:10.1038/nrn2297

80.   Miller AH, Berk M, Bloch G, et al. Advancing precision psychiatry and targeted treatments: Insights from immunopsychiatry. *Brain Behav Immun*. Mar 2025;125:319-329. doi:10.1016/j.bbi.2025.01.002

81.   Liu FL, Lin LH, Sytwu HK, Chang DM. GDF-5 is suppressed by IL-1beta and enhances TGF-beta3-mediated chondrogenic differentiation in human rheumatoid fibroblast-like synoviocytes. *Exp Mol Pathol*. Feb 2010;88(1):163-70. doi:10.1016/j.yexmp.2009.09.019

(E) **childhood adversity**

inflammation

G x E ?

DNA methylation

(G) **genetic variation**

disease

N=4,251
blood samples
21% with
**childhood
adversity**

DNAm

SNP genotype

DNAm

SNP genotype

contextual meQTLs

➡ Regulation of **gene expression**
➡ Association with **asthma, autoimmune disorders, cardiovascular diseases and mental disorders**
➡ Enrichment for pathways implicated in the **MHC complex**
➡ Overlap with epigenetic signatures in **post-mortem brain**
➡ **Polygenic interaction reactivity score** is associated with **IL-6** in exposed individuals

created with BioRender

Graphical abstract

Figure 1

Figure 2